Urologist Dr. Fred Saad, Professor and Chairman, Department of Surgery, University of Montreal reviews the Health Canada approval of a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting: nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).